Page 193 - 2021_05-Haematologica-web

TAK1 inhibition in myeloma
ple myeloma. Am J Pathol. 2016;186(3):
678-690.
42. Fujii M, Takeda K, Imamura T, et al. Roles
of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell. 1999;10(11):3801-3813.
43. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001; 98(2):428-435.
44. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoi- etic malignancies. Semin Oncol. 2001; 28(6):551-559.
45.Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 2004;18(3):628- 635.
46. Beishline K, Azizkhan-Clifford J. Sp1 and the 'hallmarks of cancer'. FEBS J. 2015; 28282):224-258.
47. Tornin J, Martinez-Cruzado L, Santos L, et al. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma. Oncotarget. 2016;7(21):30935-30950.
48. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with
activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003;22(16): 2417-2421.
49.Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhe- sion mediated drug resistance (CAM-DR). Oncogene. 2000;19(38):4319-4327. Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances produc- tion of osteoclast-stimulating activity. Blood. 2000;96(5):1953-1960.
50.
haematologica | 2021; 106(5)
1413